Skip to content

Development of Interventions to Modulate Immune Cell Trafficking in T1D

Deadlines are 5:00 PM (Eastern). No extensions will be granted.

Milestone Date Status
Letter of Intent Required Jan 17, 2024 Passed
Application Feb 28, 2024 Passed
Award Notification Aug 31, 2024 Next
Earliest Start Oct 01, 2024

Background & Purpose

Please click on the “RFA Announcement” link above for complete information.

Informational Webinar and Q&A

To view the informational webinar that took place on December 13th, please click here.


JDRF, the world’s leading non-profit organization with the mission to improve the lives of people with T1D by accelerating breakthroughs for T1D, aims to catalyze and support innovative studies that enhance beta cell health and function. A potential therapeutic strategy to stop the immune mediated destruction of beta cells is to limit immune trafficking to the islets, however this approach has not been extensively evaluated in human-relevant models. The identification and validation of novel strategies to target islet homing pathways while avoiding broad immunosuppression is of high interest for this funding opportunity.

The goal of this funding opportunity is to accelerate the identification and validation of reagents that promote immune rebalance and the protection of beta cell function through modulating the trafficking of immune cells to the pancreatic islets. Proposals submitted for this opportunity should describe the preclinical or clinical development of therapeutic strategies targeting the trafficking of disease-relevant immune cell populations. This program will award grants of up to $900k over 3 years.